Equity research analysts from several major investment banks and healthcare-focused financial institutions cover Foghorn Therapeutics (NASDAQ: FHTX), issuing periodic consensus ratings, earnings previews, and 12-month price targets. These analysts closely monitor the company's clinical trial readouts in oncology and genetic disorders to evaluate its developmental milestones.